TheraVet announced the appointment of Rodolphe Lebrun as Chief Financial Officer. Since 2016, Rodolphe acts as a strategic advisor to small and large biotech and medtech companies on their financing, business development and M&A activities. Before joining TheraVet, Rodolphe Lebrun held the position of CFO at Graftys, an orthobiology company specialized in the development, manufacture and marketing of calcium phosphate-based synthetic bone substitutes, during the year 2020, marked by the onset of the Covid-19 pandemic.

In this position, he was involved through active cost management and the implementation of non-dilutive financing, enabling the company to successfully navigate in this uncertain period. Prior to this, he was for over 2 years Director of KPMG Belgium's Life Sciences Practice, paying particular attention to R&D-related topics as well as marketing and operational strategy. Between 2014 and 2016, he worked for the biotech company AbbVie as Customer Excellence Director and member of its Executive Committee for Belgium and Luxembourg.

Prior to this, Rodolphe spent almost 5 years with McKinsey & Company, where he was focused on defining operational strategy and leading operational excellence transformations in major pharmaceutical and medtech groups, as well as hospitals. Rodolphe is a graduate of the Faculté Polytechnique de Mons, the Institut Supérieur de l'Aéronautique et de l'Espace (ISAE Toulouse) and the Solvay Brussels School of Economics and Management. Rodolphe's role in TheraVet will be to optimize the Company's financial structure to ensure rigorous allocation of financial resources, and to implement and execute the Company's financial strategy.

He will also be responsible for pursuing and strengthening the Company's cost control policy, and for managing the Company's cash flow on a day-to-day basis.